Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Metformin/Vildagliptin vs Galvumet in Healthy Subjects
NCT06103747Phase 1Completed
- Sponsor
- Research Laboratory of Clinical and Experimental Pharmacology
- Start
- Feb 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vildagliptin + metformin in type 2 diabetes mellitus (T2DM), sponsored by Research Laboratory of Clinical and Experimental Pharmacology. Primary endpoint: Maximum Plasma Concentration at 4 hours. Started Feb 2023; status: completed.
02
Drugs
vildagliptin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06103747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06103747.